Shattuck Labs (NASDAQ:STTK) Director Clay Siegall Buys 62,500 Shares

Shattuck Labs, Inc. (NASDAQ:STTK) Director Clay Siegall purchased 62,500 shares of the stock in a transaction dated Tuesday, June 9th. The shares were bought at an average price of $4.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the director directly owned 318,608 shares of the company’s stock, valued at approximately $1,274,432. This represents a 24.40% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK opened at $4.18 on Friday. The company has a fifty day moving average of $6.38 and a 200-day moving average of $4.94. The company has a market capitalization of $320.52 million, a PE ratio of -6.63 and a beta of 1.08. Shattuck Labs, Inc. has a 52-week low of $0.71 and a 52-week high of $8.33.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. During the same quarter last year, the company earned ($0.27) EPS. On average, equities analysts forecast that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wedbush upped their price target on shares of Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Wall Street Zen downgraded shares of Shattuck Labs from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 price target for the company in a report on Friday, June 5th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Shattuck Labs in a report on Monday. Finally, Citigroup upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, June 5th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Trading of Shattuck Labs

A number of institutional investors and hedge funds have recently bought and sold shares of STTK. AQR Capital Management LLC increased its holdings in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Shattuck Labs in the first quarter valued at $81,000. Acadian Asset Management LLC increased its holdings in Shattuck Labs by 27.6% in the first quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock valued at $243,000 after purchasing an additional 55,687 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Shattuck Labs in the second quarter valued at $44,000. Finally, Jane Street Group LLC increased its holdings in Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after purchasing an additional 278,576 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.